The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab ...

This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...

Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope: Tokyo Wednesday, January 15, 2025, 09:00 Hrs [IST] Daiichi Sankyo Com ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...

Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...

Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.

In a pooled analysis from two trials, Dato-DXd has shown promise as a treatment for advanced EGFR-mutated NSCLC.

N-iX, a global software solutions and services company, has expanded its operations to India with the opening of a new ...

ServiceNow today announced that it will release financial results for the fourth quarter and full-year ended December 31, 2024, following the close of market on Wednesday, January 29, 2025. ServiceNow ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...